$ARIA Recent Headlines Six stocks to watch 3:27 p.m.

New Post Public Reply Private Reply Replies (0) Message Board

Jan 11, 2015 at 10:38 AM

$ARIA Recent Headlines

Six stocks to watch 3:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 3:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 9:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 1:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 3:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 4:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 3:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 6:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 3:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 8:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com

Hottest Healthcare Stocks Now – ARIA ACHN KERX CLVS 12:15 p.m. Jan. 7, 2015 - InvestorPlace.com
Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's "Dead Cat Bounce" Stock 9:45 a.m. Jan. 7, 2015 - TheStreet.com
Ariad finalizes design of Iclusig dose ranging study in CP-CML 8:04 a.m. Jan. 6, 2015 - Seeking Alpha
Benzinga's Top #PreMarket Losers 7:22 a.m. Jan. 5, 2015 - benzinga.com
Is Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? - Tale of the Tape 8:55 a.m. Jan. 2, 2015 - Zacks.com
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog 2:35 p.m. Dec. 31, 2014 - Zacks.com
Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More 8:17 a.m. Dec. 30, 2014 - benzinga.com
Ariad inks Iclusig distribution deal for Central and Eastern Europe 7:55 a.m. Dec. 30, 2014 - Seeking Alpha
China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug 12:30 p.m. Dec. 28, 2014 - Seeking Alpha
Ariad Pharma inks commercialization deal in Asia 7:43 a.m. Dec. 23, 2014 - Seeking Alpha
Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve) 9:02 a.m. Dec. 19, 2014 - TheStreet.com
Mid-Afternoon Market Update: Oxford Industries Drops On Downbeat Results; Office Depot Shares Spike Higher 2:59 p.m. Dec. 11, 2014 - benzinga.com
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years 2:52 p.m. Dec. 11, 2014 - TheStreet.com
Mid-Day Market Update: Dow Jumps Over 200 Points; Staples Shares Surge On Confirmation Of Stake By Starboard Value 11:40 a.m. Dec. 11, 2014 - benzinga.com
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action? 9:14 a.m. Dec. 11, 2014 - TheStreet.com
Morning Market Losers 8:57 a.m. Dec. 11, 2014 - benzinga.com
Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers 8:56 a.m. Dec. 11, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More 7:38 a.m. Dec. 11, 2014 - 247WallSt.com
UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak 7:06 a.m. Dec. 11, 2014 - benzinga.com
Long-term follow up data for Iclusig positive 10:54 a.m. Dec. 9, 2014 - Seeking Alpha

ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015 7:35 a.m. Jan. 6, 2015 - BusinessWire - BZX
Striking Deals on Street: New Research on State Investors, NCI, Ariad, Under Armour and Meadowbrook 9:20 a.m. Dec. 31, 2014 - PR Newswire - PRF
ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries 7:35 a.m. Dec. 30, 2014 - BusinessWire - BZX
ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference 7:35 a.m. Dec. 22, 2014 - BusinessWire - BZX
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma 9:15 a.m. Dec. 18, 2014 - PR Newswire - PRF
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial 7:35 a.m. Dec. 8, 2014 - BusinessWire - BZX
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison 8:45 a.m. Nov. 25, 2014 - PR Newswire - PRF
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia 7:35 a.m. Nov. 24, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting 9:44 a.m. Nov. 6, 2014 - BusinessWire - BZX
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress 7:36 a.m. Nov. 5, 2014 - BusinessWire - BZX
ARIAD to Present at the Stifel 2014 Healthcare Conference 7:35 a.m. Nov. 4, 2014 - BusinessWire - BZX
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe 6:35 a.m. Oct. 24, 2014 - BusinessWire - BZX
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind 7:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power 7:45 a.m. Oct. 20, 2014 - PR Newswire - PRF
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics 7:40 a.m. Oct. 15, 2014 - PR Newswire - PRF
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results 6:35 a.m. Oct. 15, 2014 - BusinessWire - BZX
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency 6:44 a.m. Oct. 10, 2014 - BusinessWire - BZX
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology 6:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib 6:35 a.m. Oct. 2, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZKONG, Hagebau Push ESLs in European Retail Revamp

ESLs: The Next Step in Retail Revamp Here’s the scoop: ZKONG and hagebau are making waves in the retail scene over in Germany. They’re bringing in Electronic Shelf Labels (ESLs) to kick traditional price tags to the curb. What started as a shake-up in supermarkets now rolls into the world of home improvement retail—headline by hagebaumarkt in Selb after nearly half...

ATTACK SHARK's X60: A New Era in Gaming Audio

Gaming Audio Gets a Power Boost with X60 We're diving headfirst into an era where gaming headsets promise more bells and whistles than ever before. This isn't just some random gadget plopped on the market. ATTACK SHARK's X60 Gaming Headset is strutting in, guns blazing, ready to take on the heavyweights in the competitive gaming world. It's not just about being another...

HR HealthCare Foundation: New Chapter of Giving

HR HealthCare Reaffirms Commitment Through New Foundation The corporate world didn't see this one coming. On October 29, 2026, HR HealthCare, a stalwart in the healthcare products arena, has decided to double down on its benevolent side by establishing the HR HealthCare Foundation. It ain't just about selling widgets anymore; it's about making a genuine impact outside the...

Keith Strachan Elevates The Master Group's Strategy

Strachan Steps Up as Chief Commercial Officer Keith Strachan is stepping into the role of Chief Commercial Officer at The Master Group—big news up in St-Bruno-de-Montarville. Now, those not neck-deep in HVAC-R might shrug this one off, but for those eyeing the industry, this is where the cards start to shuffle in North America. Master’s shift isn't just paper-pushing;...

Kanazawa's Winter Crab Course Brings Flavor to Life

An Unexpected Dance of Flavors Nestled in Kanazawa’s Nishi Chaya District, Canisienne Kanazawa isn’t just another eatery—it’s an engulfing dive into the world of winter crab extravagance. Picture yourself at an intimate, eight-seat counter, where chefs transform live crabs into culinary masterpieces right before your eyes. From early November to the end of...

Nicely Network: A Game-Changer for B2B SaaS Marketing

Navigating the Reddit Marketing Labyrinth Life ain't a walk in the park for marketers these days, especially in the tech and SaaS arenas. Some folks seem to have cracked the code—or at least one part of it. Enter Nicely Network, which has just snagged the crown as the Best Reddit Marketing Agency for B2B SaaS & Software Companies, thanks to its knack for connecting...

FMC Corporation's Q3 2026: Tough Quarter, Dim Outlook

FMC's Challenging Third Quarter Let's cut through the red tape right away—FMC Corporation just rolled out its Q3 2026 results, and boy, it wasn't pretty. Revenue plummeted to $106 million—a staggering drop from the $542 million of the same quarter last year. If you're wondering how such a bruising came about, you can thank the hefty commercial actions they pulled out...

Gate's Strong Q3: Sales Growth & Rising Margins

Solid Performance Boosts Confidence Gates Industrial came out swinging with their third-quarter results for 2026, showing some financial prowess that would make even the skeptics raise an eyebrow. Net sales climbed to a hefty $903.6 million, advancing 5.6% from the same time last year. It's not just smoke—core sales jumped 5.5%, signaling they're doing a bit more than...

Wood Partners Expands Charlotte Footprint with New Project

Charlotte's Expansion Beckons New Development at Village Park Charlotte's skyline is about to get a new neighbor in a growing district, as Wood Partners is set to break ground yet again, unveiling its ambitious plans for Village Park. This is not just a hodgepodge construction talk—it’s the company’s latest effort to plant its flag deep in the heart of the Queen...

Ensign Group Faces Lawsuit: Investors Weigh Options

Trouble Brewing for Ensign Group Investors There's no beating around the bush: The Ensign Group, Inc. (NASDAQ: ENSG) is caught up in a mess, and this isn't your run-of-the-mill kerfuffle. We've got a class action lawsuit on our hands, backed by the DJS Law Group. They’re not a bunch to take lightly; they’ve got experience with scalps in securities litigation. The...